Further developments with antisense treatment for myasthenia gravis

We present further developments in the study of the antisense oligonucleotide EN101. Ongoing in vitro and in vivo studies demonstrate that EN101 is a TLR9‐specific ligand that can suppress pro‐inflammatory functions and shift nuclear factor kappa B (NF‐κB) from the pro‐inflammatory canonical pathway to the anti‐inflammatory alternative pathway, which results in decreases acetylcholinesterase (AChE) activity. Preliminary results of a double‐blinded phase II cross‐over study compared 10, 20, and 40 mg EN101 administered to patients with myasthenia gravis. Patients were randomly assigned to one of three treatment groups in weeks 1, 3, and 5 and received their pretreatment dose of pyridostigmine in weeks 2 and 4. Thus far, all doses show a decrease in QMG scores, with a greater response to higher doses.

Authors: Sussman, J.D, .Argov, Z., Wirguin, Y., Apolski, S., Milic-Rasic, V. and Soreq, H.
Year of publication: 2012
Journal: Annals of the New York Academy of Science, 1275, 13-16

Link to publication:


“Working memory”